The estimated Net Worth of Peter G Traber is at least $1.04 Million dollars as of 25 September 2023. Dr Traber owns over 705 units of Selecta Biosciences Inc stock worth over $397,607 and over the last 12 years he sold SELB stock worth over $52,044. In addition, he makes $587,599 as Chief Medical Officer at Selecta Biosciences Inc.
Dr has made over 22 trades of the Selecta Biosciences Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 705 units of SELB stock worth $747 on 25 September 2023.
The largest trade he's ever made was exercising 100,000 units of Selecta Biosciences Inc stock on 13 June 2018 worth over $87,000. On average, Dr trades about 6,558 units every 83 days since 2012. As of 25 September 2023 he still owns at least 451,826 units of Selecta Biosciences Inc stock.
You can see the complete history of Dr Traber stock trades at the bottom of the page.
Dr. Peter G. Traber M.D. is the Chief Medical Officer at Selecta Biosciences Inc.
As the Chief Medical Officer of Selecta Biosciences Inc, the total compensation of Dr D at Selecta Biosciences Inc is $587,599. There are 3 executives at Selecta Biosciences Inc getting paid more, with Carsten Brunn having the highest compensation of $1,986,500.
Dr D is 66, he's been the Chief Medical Officer of Selecta Biosciences Inc since . There are 4 older and 12 younger executives at Selecta Biosciences Inc. The oldest executive at Selecta Biosciences Inc is Patrick Zenner, 73, who is the Independent Director.
Peter's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 65 GROVE STREET, WATERTOWN, MA, 02472.
Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit..., and Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Selecta Biosciences Inc executives and other stock owners filed with the SEC include: